DSM wins exclusive licence for innovative drug delivery technology

Published: 12-Mar-2009
Research & Development

DSM Biomedical, a division of Dutch global life sciences and materials company, Royal DSM, has obtained an exclusive worldwide licence for a drug and biologic delivery system developed by MediVas, a San Diego-based biomedical company.


DSM Biomedical, a division of Dutch global life sciences and materials company, Royal DSM, has obtained an exclusive worldwide licence for a drug and biologic delivery system developed by MediVas, a San Diego-based biomedical company.

DSM Biomedical said the delivery system would open up a number of opportunities for next-generation drug delivery when integrated into its Trancerta platform.

MediVas' technology is based on a set of polymers exclusively licensed from Cornell University, which are biodegradable, biocompatible and bioabsorbable. Furthermore, they are non-inflammatory and allow greater control over the rate and duration of release of their therapeutic payload.

The technology can be used with a diverse group of drug candidates, from proteins, peptides and nucleic acids to small molecule drugs, thus expanding the possible application areas of the Trancerta platform.

DSM's licence applies to drug delivery systems aimed at treating ophthalmic, (cardio)vascular, musculoskeletal diseases and at providing general pain relief. MediVas will focus its r&d on nanoparticle-based therapies in oncology, immunology and on the delivery of nucleic acids.

"Through this deal we bring the first biodegradable polymer into DSM's biomedical portfolio, which significantly enhances our materials competences," said Steve Hartig, president of DSM Biomedical.

"The licence with DSM is an ideal strategic fit which will accelerate the efforts of MediVas to commercialise its novel biopolymer technology," added Kenneth Carpenter, chairman and ceo of MediVas.

  • Companies:
  • dsm-firmenich
See more

You may also like

Ingredients

The roadmap to success in the cannabinoid drug development journey

Read more
The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
  4. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  5. Efficient PFAS-free degassing of aqueous solutions New silicone-based degassing chamber eliminates the risk of PFAS contamination

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Ingredients

The roadmap to success in the cannabinoid drug development journey

The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile
Ingredients

CBD: the new frontier in medical science

Early stage drug development plays an important role in expanding treatment options that will support the health of patients globally. To create bespoke drug products, it is important to explore and understand the benefits of new actives emerging on the market, such as cannabidiol (CBD), explains Kelsey Achenbach, Senior Director, Pharma and Medical Nutrition at DSM
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Can new discoveries prevent an antibiotic Armageddon?

Governments are waking up to the catastrophe of drug resistance and healthcare without antibiotics. But is extra funding the answer or could the pharma industry be doing more?
Ingredients

Firmenich opens R&D centre for fragrances, flavours and ingredients in Shanghai

Aims to accelerate and expand development pipeline in China and Asia Pacific
Manufacturing

DSM launches InnoSyn route scouting services

To meet r&d outsourcing needs
Manufacturing

Chemspec News: DSM and Novacta enter C. difficile project

DSM BioSolutions has entered into an agreement with Novacta Biosystems in Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule
Ingredients

DSM and Crucell sign PER.C6(R) licence agreements

<p>DSM Biologics, a division of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell have signed commercial licence agreements with Hungary-based Gedeon Richter and GSK, which will allow both companies to develop biopharmaceuticals on the PER.C6(R) platform.</p>
Subscribe now